Proactive Investors - Run By Investors For Investors

Avacta firmly focused on first-in-human Affimer therapeutic trial

Alastair Smith, chief executive of Avacta Group PLC (LON:AVCT) tells Proactive London's Andrew Scott all is on track to begin a Phase I clinical trial of its first Affimer therapeutic candidate next year.

The company is soon to start manufacturing its PD-L1 inhibitor – called AVA004-251 – which will then allow it to file a clinical trial application, asking regulators to let it test the drug on humans.

 
View full AVCT profile View Profile

Avacta Group PLC Timeline

CN Research
April 09 2019

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use